04/08/2026
Why we choose Vitti Labs for our umbilical cord tissue 🤍
At AIMX, we don’t just follow the industry, we partner with those who are shaping it.
Recently, Vitti Labs prevailed in a federal lawsuit against the FDA over how umbilical cord tissue is regulated. The court ruled that the FDA’s interpretation of “minimal manipulation” was incorrect, reinforcing a broader, patient focused understanding of how these tissues should be evaluated.
Congratulations to Philipp Vitti and the entire Vitti Labs team on this important milestone.
This recent U.S. District Court decision provides meaningful reaffirmation around the interpretation of “minimal manipulation” within the Section 361 HCT/P regulatory framework. Decisions like this are important to ensure that manufacturers and medical professionals have their rights protected and the appropriate regulatory practices of the human tissue banking industry, specifically umbilical cord-based products are conducted.
We are proud to distribute Vitti Labs 361 Human Cellular Tissue Products, supporting providers through a combination of scientific innovation, regulatory discipline, and real-world clinical experience.
If you are looking to better understand this space or evaluate products for your practice, feel free to reach out.
https://tinyurl.com/3e55pfzk
